Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Conditions
Interventions
GVAX Pancreas
CRS-207
+1 more
Locations
10
United States
H. Lee Moffitt Cancer Center
Tampa, Florida, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
Baltimore, Maryland, United States
National Cancer Institute
Bethesda, Maryland, United States
Washington University School of Medicine
St Louis, Missouri, United States
NYU Langone Medical Center
New York, New York, United States
Herbert Irving Comprehensive Cancer Center of Columbia University
New York, New York, United States
Start Date
September 21, 2011
Primary Completion Date
October 1, 2016
Completion Date
February 10, 2017
Last Updated
May 8, 2018
NCT07409272
NCT05065801
NCT04605913
NCT06662006
NCT07296341
NCT06361888
Lead Sponsor
Aduro Biotech, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions